Alesta Therapeutics

About Alesta Therapeutics

Alesta Therapeutics, founded in 2021 and based in Leiden, Netherlands, is a clinical-stage biotechnology company focused on developing therapies for rare diseases. The company emerged from stealth in January 2025 with an oversubscribed Series A financing round of €65 million ($67 million). This funding was co-led by Frazier Life Sciences and Droia Ventures, with participation from Novartis Venture Fund, RTW Investments, RV Invest, Thuja Capital, and SSI Strategy. The company is led by CEO Ilan Ganot, a former investment banker who entered the biotech field after his son's diagnosis with Duchenne muscular dystrophy.

Alesta's business model centers on the in-house development and clinical progression of small molecule drugs designed for oral administration. Its primary market is patients with underserved rare genetic disorders. The company's lead asset, ALE1, is a therapeutic candidate for hypophosphatasia (HPP), a rare genetic condition that impairs bone and tooth mineralization. ALE1, in-licensed from 1cBio, works by inhibiting a novel target to lower levels of inorganic pyrophosphate (PPi), a key metabolite in the disease's pathology. Preclinical data has shown that oral administration of ALE1 reduces PPi levels in animal models, and the company is preparing for clinical studies expected to start in 2025.

The company is also developing a second candidate, ALE2, which targets specific forms of Charcot-Marie-Tooth (CMT) disease, a group of inherited neuropathies. This condition is caused by mutations in tRNA synthase genes, affecting over 10,000 people across the U.S., Europe, and Japan. ALE2 is a GCN2 inhibitor that aims to address chronic neurotoxicity caused by the overactivation of the Integrated Stress Response (ISR). The kinase GCN2 is a sensor for amino acid deprivation and a key regulator of the ISR; inhibiting it is a therapeutic strategy for various diseases where this pathway is implicated, including certain cancers and genetic disorders. By targeting GCN2, ALE2 has the potential to slow or halt the progression of CMT symptoms.